{"id":"https://openalex.org/W2080449229","doi":"https://doi.org/10.1111/j.1463-1326.2011.01518.x","title":"Long\u2010term treatment with empagliflozin, a novel, potent and selective SGLT\u20102 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats","display_name":"Long\u2010term treatment with empagliflozin, a novel, potent and selective SGLT\u20102 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats","alternate_titles":[],"publication_year":2011,"publication_date":"2011-11-13","ids":{"openalex":"https://openalex.org/W2080449229","doi":"https://doi.org/10.1111/j.1463-1326.2011.01518.x","mag":"2080449229","pmid":"https://pubmed.ncbi.nlm.nih.gov/21985693"},"language":"en","primary_location":{"id":"doi:10.1111/j.1463-1326.2011.01518.x","doi":"https://doi.org/10.1111/j.1463-1326.2011.01518.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2011.01518.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2080449229"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061499869","display_name":"Leo H. Thomas","orcid":"https://orcid.org/0000-0002-2156-7298","observed_orcids":["https://orcid.org/0000-0002-2156-7298"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"L. Thomas","raw_affiliation_strings":["Department of CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany. leo.thomas@boehringer-ingelheim.com","Department of CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","These authors have equally contributed to this work"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany. leo.thomas@boehringer-ingelheim.com","institution_ids":["https://openalex.org/I1330995197"]},{"raw_affiliation_string":"Department of CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]},{"raw_affiliation_string":"These authors have equally contributed to this work","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082492698","display_name":"Rolf Grempler","orcid":"https://orcid.org/0000-0002-9291-4947","observed_orcids":["https://orcid.org/0000-0002-9291-4947"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"R. Grempler","raw_affiliation_strings":["Department of CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","These authors have equally contributed to this work"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]},{"raw_affiliation_string":"These authors have equally contributed to this work","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"M. Eckhardt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Eckhardt","raw_affiliation_strings":["Department of Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075029211","display_name":"Frank Himmelsbach","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"F. Himmelsbach","raw_affiliation_strings":["Department of Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":null,"display_name":"A. Sauer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. Sauer","raw_affiliation_strings":["Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032965517","display_name":"Thomas Klein","orcid":"https://orcid.org/0000-0001-5762-9166","observed_orcids":["https://orcid.org/0000-0001-5762-9166"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"T. Klein","raw_affiliation_strings":["Department of CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062761332","display_name":"Peter Eickelmann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"P. Eickelmann","raw_affiliation_strings":["Department of CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101439694","display_name":"Michael Mark","orcid":"https://orcid.org/0000-0002-8284-5773","observed_orcids":["https://orcid.org/0000-0002-8284-5773"]},"institutions":[{"id":"https://openalex.org/I1330995197","display_name":"Boehringer Ingelheim (Germany)","ror":"https://ror.org/00q32j219","country_code":"DE","type":"company","lineage":["https://openalex.org/I1330995197"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Mark","raw_affiliation_strings":["Department of CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co.KG, Biberach, Germany","institution_ids":["https://openalex.org/I1330995197"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5061499869"],"corresponding_institution_ids":["https://openalex.org/I1330995197"],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":null,"fwci":3.9461,"has_fulltext":false,"cited_by_count":57,"citation_normalized_percentile":{"value":0.93642365,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"14","issue":"1","first_page":"94","last_page":"96"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11140","display_name":"Natural Antidiabetic Agents Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/empagliflozin","display_name":"empagliflozin","score":1.0},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.9509999752044678},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9860000014305115},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.9200000166893005},{"id":"https://openalex.org/keywords/metabolic-syndrome","display_name":"metabolic syndrome","score":0.777999997138977},{"id":"https://openalex.org/keywords/insulin-sensitivity","display_name":"insulin sensitivity","score":0.7950000166893005},{"id":"https://openalex.org/keywords/urinary-glucose-excretion","display_name":"urinary glucose excretion","score":0.7960000038146973},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.9369999766349792},{"id":"https://openalex.org/keywords/hyperinsulinemic-euglycemic-clamp","display_name":"hyperinsulinemic-euglycemic clamp","score":0.9120000004768372},{"id":"https://openalex.org/keywords/zucker-diabetic-fatty-rats","display_name":"Zucker diabetic fatty rats","score":0.875}],"concepts":[{"id":"https://openalex.org/C2775887513","wikidata":"https://www.wikidata.org/wiki/Q5373824","display_name":"Empagliflozin","level":4,"score":0.997538685798645},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.6338800191879272},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6060235500335693},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5794791579246521},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5293396711349487},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5206336379051208},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.4676351845264435},{"id":"https://openalex.org/C10146269","wikidata":"https://www.wikidata.org/wiki/Q185557","display_name":"Excretion","level":2,"score":0.46375444531440735},{"id":"https://openalex.org/C2778808658","wikidata":"https://www.wikidata.org/wiki/Q2975183","display_name":"Glucose clamp technique","level":5,"score":0.4606137275695801},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4067924916744232},{"id":"https://openalex.org/C2777391703","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin resistance","level":3,"score":0.2084428369998932},{"id":"https://openalex.org/C3017594256","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin sensitivity","level":4,"score":0.19235169887542725}],"mesh":[{"descriptor_ui":"D000077203","descriptor_name":"Sodium-Glucose Transporter 2 Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001559","descriptor_name":"Benzhydryl Compounds","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011924","descriptor_name":"Rats, Zucker","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015309","descriptor_name":"Glucose Clamp Technique","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D024821","descriptor_name":"Metabolic Syndrome","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D024821","descriptor_name":"Metabolic Syndrome","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1463-1326.2011.01518.x","doi":"https://doi.org/10.1111/j.1463-1326.2011.01518.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1463-1326.2011.01518.x","pdf_url":null,"source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmid:21985693","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21985693","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":5,"referenced_works":["https://openalex.org/W1996143753","https://openalex.org/W2091203103","https://openalex.org/W2134855422","https://openalex.org/W2154020052","https://openalex.org/W2171786511"],"related_works":["https://openalex.org/W2068405048","https://openalex.org/W2142032747","https://openalex.org/W2318489656","https://openalex.org/W2173615285","https://openalex.org/W2330830805","https://openalex.org/W3159116878","https://openalex.org/W4389023910","https://openalex.org/W2123655868","https://openalex.org/W2123775627","https://openalex.org/W2042291132"],"abstract_inverted_index":{"Empagliflozin":[0],"is":[1,10],"a":[2,96],"potent,":[3],"selective":[4],"sodium":[5],"glucose":[6,55,61,70],"co-transporter-2":[7],"inhibitor":[8],"that":[9],"in":[11,29,40,50,53,59],"development":[12,135],"for":[13,138],"the":[14,28,134,139],"treatment":[15,140],"of":[16,22,33,38,47,98,114,136,141],"type":[17,142],"2":[18,143],"diabetes.":[19,144],"This":[20],"series":[21],"studies":[23],"was":[24],"conducted":[25],"to":[26,86],"assess":[27],"vivo":[30],"pharmacological":[31],"effects":[32],"single":[34],"or":[35],"multiple":[36,64,127],"doses":[37,46,65,128],"empagliflozin":[39,48,125,137],"Zucker":[41],"diabetic":[42],"fatty":[43],"rats.":[44],"Single":[45],"resulted":[49],"dose-dependent":[51],"increases":[52],"urinary":[54],"excretion":[56],"and":[57,76,80,102,106],"reductions":[58],"blood":[60,69],"levels.":[62],"After":[63,88],"(5":[66],"weeks),":[67],"fasting":[68],"levels":[71,92],"were":[72,93],"reduced":[73,94],"by":[74,100],"26":[75],"39%":[77],"with":[78,104,116,124],"1":[79,105],"3":[81,107],"mg/kg":[82,108],"empagliflozin,":[83,109],"respectively,":[84,110],"relative":[85],"vehicle.":[87,117,130],"5":[89],"weeks,":[90],"HbA1c":[91],"(from":[95],"baseline":[97],"7.9%)":[99],"0.3":[101],"1.1%":[103,115],"versus":[111,129],"an":[112],"increase":[113],"Hyperinsulinaemic-euglycaemic":[118],"clamp":[119],"indicated":[120],"improved":[121],"insulin":[122],"sensitivity":[123],"after":[126],"These":[131],"findings":[132],"support":[133]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2080449229","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":6},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":9},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
